NovoNorm
(repaglinide)ApprovedSmall molecule
Repaglinide is used to help people with type 2 diabetes control their blood sugar levels by stimulating the pancreas to release insulin, especially when taken before meals.[2] NovoNorm is currently approved and in use across 9 indications[4].[1]
NovoNorm is one of 256 small molecule programs targeting Cystic Fibrosis. It is currently in Approved.
9
Indications
61
Total Trials
3
Active Trials
255
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1NovoNorm
GGemini Therapeutics, Inc.
Approved
Cabometyx
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Alinamin
RochePhase 3
Piflufolastat
NovartisPhase 3
AAA817
NovartisPhase 3
Lupron
Radiation Therapy Oncology GroupPhase 3
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes15 trials
Show 12 more trials
Interaction12 trials
Show 9 more trials
Single Dose3 trials
Tics3 trials
20 more indications
Observational Study2 trials
Midazolam2 trials
Type 2 Diabetes Mellitus2 trials
ART2 trials
Atorvastatin2 trials
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06601517·30 enrolled
Obese Patients1 trial
Caffeine1 trial
Endothelial Function1 trial
Advanced Solid Tumor1 trial
Cystic Fibrosis1 trial
Diabetes1 trial
Diabetes Therapy to Improve BMI and Lung Function in CF
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00072904·108 enrolled
Lymphoma1 trial
Type 2 Diabetic Patients1 trial
Safety and Efficacy1 trial
Advanced Malignancies1 trial
Regulatory
FDA Approval Timeline[5]
Dec 22, 1997
PRANDIN
NDA NDA020741
Sources
References
- [1]
- [2]MedlinePlus Drug Information — NovoNorm drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for repaglinide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sulfonylurea Receptor 1, Kir6.2 Blocker[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGemini Therapeutics, Inc.